NASDAQ:BTTC

Black Titan Q1 2026 Earnings Results & Report

Black Titan logo
$0.26 0.00 (-0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$0.26 0.00 (-0.69%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Titan reported Q1 2026 earnings on February 18, 2026. The company reported EPS of -$1.8110.

Earnings Announcement Details

Quarter
Q1 2026
Time
After Market Closes

Black Titan EPS Results

Actual EPS
-$1.8110
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Black Titan Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Black Titan Q1 2026 Earnings FAQ

Black Titan (NASDAQ:BTTC) reported earnings of -$1.8110 per share for Q1 2026. The report was announced on Wednesday, February 18, 2026.

Black Titan Earnings Headlines

Black Titan Corp (BTTC)
The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
Black Titan Corp BTTC
See More Black Titan Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Black Titan? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Titan and other key companies, straight to your email.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

View Black Titan Profile